サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：患者腫瘍組織移植（PDX）モデルの世界市場：腫瘍タイプ別、モデル別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2023年～2030年予測
市場調査レポート
商品コード
1351394

患者腫瘍組織移植（PDX）モデルの世界市場：腫瘍タイプ別、モデル別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2023年～2030年予測

Patient Derived Xenograft (PDX) Model Market, By Tumor Type, By Model, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 246 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
患者腫瘍組織移植（PDX）モデルの世界市場：腫瘍タイプ別、モデル別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2023年～2030年予測
出版日: 2023年08月01日
発行: AnalystView Market Insights
ページ情報: 英文 246 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の患者腫瘍組織移植（PDX）モデルの市場規模は、2022年は2億9,060万米ドルとなり、2023年から2030年にかけてCAGR 13.2％で拡大すると予想されています。

患者腫瘍組織移植（PDX）モデル市場 - 市場力学

  • 世界のがん有病率の増加が市場成長を牽引
  • 世界中でがんの有病率が高まっていることが、予測期間中の市場成長を促進すると予想されています。例えば、米国国立がん研究所（National Cancer Institutes）が発表した報告書によると、2022年1月時点の米国におけるがん生存者数は1,810万人です。これは総人口の約5.4％に相当します。米国では、62万3,405人が転移性乳がん、前立腺がん、肺がん、大腸がん、膀胱がん、メラノーマに罹患しており、2025年には69万3,452人に増加すると予測されています。さらに、英国がん研究所のデータによると、罹患率が安定し、人口増加と高齢化が現在のペースで続けば、2040年までに世界で毎年2,800万人のがん患者が新たに発生すると予測されています。これは2020年比で54.9％の増加であり、女性（48.8％増）よりも男性（60.6％増）の方が増加率が大きいと予測されています。したがって、前述の事実は予測期間中の市場成長を促進します。

患者腫瘍組織移植（PDX）モデル市場 - セグメンテーション分析

  • 患者腫瘍組織移植（PDX）モデルの世界市場は、腫瘍タイプ、モデル、エンドユーザー、地域に基づいてセグメント化されます。
  • 腫瘍タイプに基づき、世界の患者腫瘍組織移植（PDX）モデル市場は、前立腺がん、膵臓がん、肺がん、乳がん、その他に区分されます。予測期間中、乳がん分野が市場を独占すると予想されます。乳がんは、発見や治療方法が時代とともに大きく改善されたにもかかわらず、依然として世界の女性の死亡原因の第1位を占めています。現在の医薬品では、乳がんを含め、腫瘍は極めて多様な集団で構成されているため、腫瘍を破壊することは課題です。乳がんの腫瘍間の不均一性により、in vitroやin vivoで作成された細胞株など、一般的に使用されるがんモデルを用いて治療効果を正確に予測することも困難です。その結果、ヒトの悪性腫瘍の起源の多様性をより現実的に描写するために、PDXモデルが作成されるようになっています。これらのモデルにより、乳がん治療法の改善が期待されます。それにより、予測期間中の同分野の成長を牽引します。
  • 患者腫瘍組織移植（PDX）モデル市場 - 地理的洞察
  • 地域的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスを展開する国によってさらに分けられます。北米は、がんの有病率の増加により、予測期間中に市場を独占すると予想されています。さらに、研究開発投資の増加も業界拡大を後押しする重要な要因です。さらに、この地域には主要企業が存在するため、市場の成長を促進すると期待されています。例えば、2023年4月、2023年米国がん研究協会（AACR）年次総会において、パラダイムシフトする治療薬を通じてがん患者のアンメットメディカルニーズに対応することを目指すバイオ医薬品企業であるVincerx Pharma, Inc.は、さまざまな腫瘍型にわたるPDXマウスモデルおよび転移性PDXマウスモデルにおけるVIP236単剤治療の前臨床データをポスター発表しました。したがって、このような取り組みがこの地域の市場成長を促進すると期待されます。

患者腫瘍組織移植（PDX）モデル市場 - 競合情勢

市場で事業を展開する主要企業は以下の通りである：WuXi AppTec、XenTech、Crown Bioscience、Altogen Labs、Envigo、Charles River Laboratories、Oncodesign、Hera Biolabs、The Jackson Laboratory、Abnova Corp.

目次

第1章 患者腫瘍組織移植（PDX）モデル市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 患者腫瘍組織移植（PDX）モデルの主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 患者腫瘍組織移植（PDX）モデル産業の研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 患者腫瘍組織移植（PDX）モデル市場：COVID-19の影響分析

  • 新型コロナウイルス感染症以前の影響分析
  • 新型コロナウイルス感染症後の影響分析

第6章 患者腫瘍組織移植（PDX）モデル市場情勢

  • 患者腫瘍組織移植（PDX）モデルの市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 患者腫瘍組織移植（PDX）モデル市場 - 腫瘍タイプ別

  • 概要
    • 腫瘍タイプ別のセグメントシェア分析
    • 前立腺がん
    • 膵臓がん
    • 肺がん
    • 乳がん
    • その他

第8章 患者腫瘍組織移植（PDX）モデル市場 - モデル別

  • 概要
    • モデル別セグメントシェア分析
    • マウス
    • ネズミ

第9章 患者腫瘍組織移植（PDX）モデル市場 - エンドユーザー別

  • 概要
    • エンドユーザー別のセグメントシェア分析
    • 製薬会社・バイオ医薬品会社
    • 学術研究機関
    • CRO・CDMO

第10章 患者腫瘍組織移植（PDX）モデル市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析 - 患者腫瘍組織移植（PDX）モデル業界

  • 競合ダッシュボード
  • 企業プロファイル
    • WuXi AppTec
    • XenTech
    • Crown Bioscience
    • Altogen Labs
    • Envigo
    • Charles River Laboratories
    • Oncodesign
    • Hera Biolabs
    • The Jackson Laboratory
    • Abnova Corp.

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Patient Derived Xenograft (PDX) Model Market: Tumor Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Tumor Type
  • TABLE Global Patient Derived Xenograft (PDX) Model Market, by Tumor Type 2018-2030 (USD Million)
  • TABLE Patient Derived Xenograft (PDX) Model Market: Model Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Model
  • TABLE Global Patient Derived Xenograft (PDX) Model Market, by Model 2018-2030 (USD Million)
  • TABLE Patient Derived Xenograft (PDX) Model Market: End User Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End User
  • TABLE Global Patient Derived Xenograft (PDX) Model Market, by End User 2018-2030 (USD Million)
  • TABLE Patient Derived Xenograft (PDX) Model Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Patient Derived Xenograft (PDX) Model Market, by Region 2018-2030 (USD Million)
  • TABLE North America Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE North America Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE North America Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)
  • TABLE Europe Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE Europe Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE Europe Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)
  • TABLE Asia Pacific Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE Asia Pacific Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)
  • TABLE Latin America Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE Latin America Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE Latin America Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)

List of Figures

  • FIGURE Patient Derived Xenograft (PDX) Model Market Segmentation
  • FIGURE Market research Modelology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Tumor Type segment market share analysis, 2022 & 2030
  • FIGURE Tumor Type segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Model segment market share analysis, 2022 & 2030
  • FIGURE Model segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE End User segment market share analysis, 2022 & 2030
  • FIGURE End User segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE Europe Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE Asia Pacific Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE Latin America Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE Middle East and Africa Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Patient Derived Xenograft (PDX) Model Market share analysis by country, 2022
  • FIGURE Germany Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Patient Derived Xenograft (PDX) Model Market share analysis by country, 2022
  • FIGURE India Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Patient Derived Xenograft (PDX) Model Market share analysis by country, 2022
  • FIGURE Brazil Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Patient Derived Xenograft (PDX) Model Market share analysis by country, 2022
  • FIGURE Saudi Arabia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
目次
Product Code: ANV1643

REPORT HIGHLIGHT

Patient Derived Xenograft (PDX) Model Market size was valued at USD 290.6 Million in 2022, expanding at a CAGR of 13.2% from 2023 to 2030.

Patient-derived xenografts (PDX) are cancer models in which a patient's tumor tissue or cells are implanted into immunocompromised or humanized mice. This procedure involves xenotransplantation. To maintain the development of cancer after it has been removed from a patient, PDX models are employed. This allows for the monitoring of tumor development in the lab, including how it responds to various therapy choices. A PDX model from a given patient can be evaluated against a variety of medicines in a 'personalized oncology' approach, or cohorts of PDX models can be used to assess the therapeutic effectiveness of a drug against distinct forms of cancer.

Patient Derived Xenograft (PDX) Model Market - Market Dynamics:

  • The growing prevalence of cancer across the globe drives the market growth
  • The growing prevalence of cancer across the globe is expected to drive market growth during the forecast period. For instance, according to the report published by National Cancer Institutes, there would be 18.1 million cancer survivors in the US as of January 2022. This is equivalent to around 5.4% of the total population. In the United States, 623,405 persons have metastatic breast, prostate, lung, colorectal, bladder, or melanoma, and by the year 2025, that number is projected to rise to 693,452. Moreover, as per the data by Cancer Research UK, it is anticipated that there will be 28 million new cancer cases globally each year by 2040 if incidence remains steady and population growth and ageing continue at current rates. This is a 54.9% increase over 2020, and it is predicted to be larger in males (60.6% increase) than in women (48.8% increase). Thus, the aforementioned facts drive the market growth during the forecast period.

Patient Derived Xenograft (PDX) Model Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Patient Derived Xenograft (PDX) Model market is estimated to grow annually at a CAGR of around 13.2% over the forecast period (2023-2030)
  • Patient Derived Xenograft (PDX) Model industry is projected to grow at a significant rate owing to the growing prevalence of cancer.
  • Based on the tumor type, the breast cancer segment is expected to dominate the market over the forecast period.
  • Based on region, North America is expected to dominate the market over the forecast period.

Patient Derived Xenograft (PDX) Model Market- Segmentation Analysis:

  • The Global Patient Derived Xenograft (PDX) Model Market is segmented based on tumor type, model, end user and Region.
  • Based on the tumor type, the global Patient Derived Xenograft (PDX) Model market is segmented into prostate cancer, pancreatic cancer, lung cancer, breast cancer and others. The breast cancer segment is expected to dominate the market during the forecast period. Breast cancer still ranks as the leading cause of death for women worldwide, despite major improvements in detection and treatment methods over time. With current medicines, it is challenging to destroy tumors since they are made up of populations that are extremely varied, including those of breast cancer. Due to the inter-tumor heterogeneity of breast cancer, it is also difficult to accurately predict therapeutic efficacy using commonly used cancer models, such as cell lines created in vitro and in vivo. As a result, PDX models have been created to more realistically depict the variability of the origins of human malignancies. These models are expected to improve breast cancer therapy modalities. Thereby, driving the segment growth over the forecast period.

Patient Derived Xenograft (PDX) Model Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period due to the increasing prevalence of cancer. Moreover, the increasing R&D investments are also an important factor that propels the industry expansion. Furthermore, the presence of key players in the region is expected to propel the market growth. For instance, in April 2023, at the 2023 American Association for Cancer Research (AACR) Annual Meeting, Vincerx Pharma, Inc., a biopharmaceutical company aiming to address the unmet medical needs of cancer patients through paradigm-shifting therapeutics, presented a poster of preclinical data of VIP236 monotherapy treatment in PDX and metastatic PDX mouse models across various tumor types. Thus, this kind of initiative is expected to drive market growth in the region.

Patient Derived Xenograft (PDX) Model Market- Competitive Landscape:

The key players operating in the market are: WuXi AppTec, XenTech, Crown Bioscience, Altogen Labs, Envigo, Charles River Laboratories, Oncodesign, Hera Biolabs, The Jackson Laboratory and Abnova Corp.

Recent Developments:

In July 2022, GemPharmatech (GemPharmatech Co., Ltd.) announced that it has entered into a strategic license agreement with Charles River Laboratories, Inc. for the exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. The goal of this agreement is to speed up the development of novel therapeutics for a variety of unmet medical needs, particularly in immuno-oncology. To produce models that will be sold starting in 2023, Charles River will create foundation colonies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET KEY PLAYERS

  • WuXi AppTec
  • XenTech
  • Crown Bioscience
  • Altogen Labs
  • Envigo
  • Charles River Laboratories
  • Oncodesign
  • Hera Biolabs
  • The Jackson Laboratory
  • Abnova Corp.

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE

  • Prostate Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Breast Cancer
  • Others

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY MODEL

  • Mice
  • Rats

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER

  • Pharmaceutical And Biopharmaceutical Companies
  • Academic & Research Institutes
  • CROs & CDMOs

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Patient Derived Xenograft (PDX) Model Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Patient Derived Xenograft (PDX) Model Market Snippet by Tumor Type
    • 2.1.2. Patient Derived Xenograft (PDX) Model Market Snippet by Model
    • 2.1.3. Patient Derived Xenograft (PDX) Model Market Snippet by End User
    • 2.1.4. Patient Derived Xenograft (PDX) Model Market Snippet by Country
    • 2.1.5. Patient Derived Xenograft (PDX) Model Market Snippet by Region
  • 2.2. Competitive Insights

3. Patient Derived Xenograft (PDX) Model Key Market Trends

  • 3.1. Patient Derived Xenograft (PDX) Model Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Patient Derived Xenograft (PDX) Model Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Patient Derived Xenograft (PDX) Model Market Opportunities
  • 3.4. Patient Derived Xenograft (PDX) Model Market Future Trends

4. Patient Derived Xenograft (PDX) Model Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Patient Derived Xenograft (PDX) Model Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Patient Derived Xenograft (PDX) Model Market Landscape

  • 6.1. Patient Derived Xenograft (PDX) Model Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Patient Derived Xenograft (PDX) Model Market - By Tumor Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Tumor Type, 2022 & 2030 (%)
    • 7.1.2. Prostate Cancer
    • 7.1.3. Pancreatic Cancer
    • 7.1.4. Lung Cancer
    • 7.1.5. Breast Cancer
    • 7.1.6. Others

8. Patient Derived Xenograft (PDX) Model Market - By Model

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Model, 2022 & 2030 (%)
    • 8.1.2. Mice
    • 8.1.3. Rats

9. Patient Derived Xenograft (PDX) Model Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
    • 9.1.2. Pharmaceutical And Biopharmaceutical Companies
    • 9.1.3. Academic & Research Institutes
    • 9.1.4. CROs & CDMOs

10. Patient Derived Xenograft (PDX) Model Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Patient Derived Xenograft (PDX) Model Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. WuXi AppTec
    • 11.2.2. XenTech
    • 11.2.3. Crown Bioscience
    • 11.2.4. Altogen Labs
    • 11.2.5. Envigo
    • 11.2.6. Charles River Laboratories
    • 11.2.7. Oncodesign
    • 11.2.8. Hera Biolabs
    • 11.2.9. The Jackson Laboratory
    • 11.2.10. Abnova Corp.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us